FDA, Industry Agree On Working Groups To Support User-Fee Negotiations
This article was originally published in The Gray Sheet
Executive Summary
The agency and industry agreed to create working groups allowing subject-matter experts to delve deeper into technical details on some of the key proposals raised thus far in user-fee reauthorization talks. Areas of focus include de novo reviews, pre-submissions and personnel recruitment challenges.